Biovest – from Chapter 11 to the edge of market filing in EU and Canada
This article was originally published in Scrip
Executive Summary
After 18 years of development, Biovest International plans to file applications for marketing approval for its personalized therapeutic cancer vaccine BiovaxID by the end of 2012 in Canada, the EU and the US.